BiotechTube

Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatment + SER-287 + Placebo for SER-287

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Dec 19, 2018 → Oct 13, 2021

NCT ID
NCT03759041

About Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatment + SER-287 + Placebo for SER-287

Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatment + SER-287 + Placebo for SER-287 is a phase 2 stage product being developed by Seres Therapeutics for Ulcerative Colitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03759041. Target conditions include Ulcerative Colitis.

What happened to similar drugs?

15 of 20 similar drugs in Ulcerative Colitis were approved

Approved (15) Terminated (5) Active (5)
✅Azathioprine + PlaceboCelltrionApproved
✅Filgotinib MaleateEisaiApproved
✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved
✅AdalimumabAbbVieApproved
✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved
✅GolimumabMerckApproved
✅GolimumabMerckApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03759041Phase 2Terminated

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
40
MirikizumabEli LillyPhase 2
35
Azathioprine + PlaceboCelltrionApproved
35
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
TacrolimusAstellas PharmaPhase 3
40
tacrolimus + PlaceboAstellas PharmaPhase 3
40
Filgotinib MaleateEisaiApproved
50
AJM300 + PlaceboEisaiPhase 3
40
GSK3050002 + PlaceboEisaiPhase 1
29
adalimumab + placeboEisaiPhase 3
40
E6007 + PlaceboEisaiPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 1
29
Arm1 + Arm 2Zydus LifesciencesPhase 2
35
Mirikizumab + MirikizumabEli LillyPhase 3
44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 2
27
Mirikizumab + PlaceboEli LillyPhase 2
35
LY4268989 + PlaceboEli LillyPhase 2
42